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Abstract
Background
Introduction of GeneXpert MTB/RIF (Xpert) assay has constituted a major breakthrough for
tuberculosis (TB) diagnostics. Several patient factors may influence diagnostic performance
of Xpert including sputum quality.
Objective
We carried out a prospective, observational, cross-sectional study to determine the effect of
sputum quality on diagnostic performance of Xpert among presumed TB patients in Uganda.
Methods
We collected clinical and demographic information and two sputum samples from partici-
pants. Staff recorded sputum quality and performed LED fluorescence microscopy and
mycobacterial culture on each sample. If both smear examinations were negative, Xpert
testing was performed. We calculated diagnostic yield, sensitivity, specificity, and other indi-
cators for Xpert for each stratum of sputum quality in reference to a standard of mycobacte-
rial culture.
Results
Patients with salivary sputum showed a trend towards a substantially higher proportion of
samples that were Xpert-positive (54/286, 19%, 95% CI 15–24) compared with those with
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all other sputum sample types (221/1496, 15%, 95% CI 13–17). Blood-stained sputum pro-
duced the lowest sensitivity (28%; 95% CI 12–49) and salivary sputum the highest (66%;
95% CI 53–77). Specificity didn’t vary meaningfully by sample types. Salivary sputum was
significantly more sensitive than mucoid sputum (+13%, 95% CI +1 to +26), while blood-
stained sputum was significantly less sensitive (-24%, 95% CI -42 to -5).
Conclusions
Our findings demonstrate the need to exercise caution in collecting sputum for Xpert and in
interpreting results because sputum quality may impact test yield and sensitivity. In particu-
lar, it may be wise to pursue additional testing should blood-stained sputum test negative
while salivary sputum should be readily accepted for Xpert testing given its higher sensitivity
and potentially higher yield than other sample types. These findings challenge conventional
recommendations against collecting salivary sputum for TB diagnosis and could inform new
standards for sputum quality.
Introduction
Introduction of the GeneXpert MTB/RIF (Xpert) assay has constituted a major breakthrough
for tuberculosis (TB) diagnostics, providing a rapid and accurate way of identifying TB
patients in high TB-burden, low-income countries [1, 2]. Nevertheless, post-implementation
studies have identified several challenges [3–6], emphasizing the need for deeper understand-
ing of clinical and operational factors affecting real-world performance [7]. Previous studies
have shown that pauci-bacillary forms of TB are more commonly identified in patients who
are HIV-seropositive [8–10] and in those who are sputum acid-fast bacilli (AFB) smear-nega-
tive, and may reduce the overall sensitivity of Xpert in reference to the standard of mycobacte-
rial culture [11–13]. However, because microscopy is also less sensitive in these populations,
these groups are also the ones most likely to benefit from Xpert, and in whom Xpert has been
especially recommended [14, 15].
A recent systematic review identified no studies describing the effect of sputum quality on
Xpert performance [16, 17]. This is surprising because international guidelines have long
emphasized macroscopic sputum quality as an important determinant of performance of
smear microscopy and culture [16, 18]. Furthermore, previous small studies have shown sali-
vary samples may be unsuitable for Xpert testing [19, 20]. Therefore, we sought to determine
the effect of sputum quality on the diagnostic performance of Xpert in a large cohort of AFB
smear-negative, presumed pulmonary TB patients in Kampala, Uganda.
Methods
Study population
From September 2008 through January 2016, we carried out a prospective, observational,
cross-sectional study to determine the effect of sputum quality on diagnostic accuracy of
Xpert. This study was carried out at Mulago National Referral Hospital, an inpatient tertiary-
care facility affiliated with Makerere University in Kampala, Uganda. We enrolled consecutive
adults with possible pulmonary TB into the Mulago Inpatient Non-invasive Diagnosis of
Pneumonia—International HIV-associated Opportunistic Pneumonia study, as previously
described [21–23]. Patients with cough2 weeks but<6 months were presumed to have TB.
Effect of sputum quality on Xpert performance
PLOS ONE | https://doi.org/10.1371/journal.pone.0180572 July 7, 2017 2 / 12
provided by D43TW009607 (CA, SK, AK, JLD) and
K24HL087713 (LH) were critical to the study. The
funder had no role in the study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
For this sub-study, we included the subset of patients with2 negative and no positive sputum
AFB-smear examinations by fluorescence microscopy. We excluded participants with sputum
collected via induction and those missing Xpert or culture results. Xpert results indeterminate
after two tests were considered missing.
Procedures
Following written informed consent, parent study participants provided clinical and demo-
graphic information and two expectorated sputum samples collected one hour apart. Trained
research staff delivered standardized instructions on proper sputum submission [24]. Labora-
tory technicians graded quality of each specimen as blood-stained, mucoid, purulent, or sali-
vary, using standardized photographs from International Union Against TB and Lung Disease
guidelines [18]. Technicians examined smears via fluorescence microscopy, and if both were
negative, they performed direct Xpert testing on the second sample. Staff interpreted sputum
quality prior to microscopy and Xpert testing and were therefore blinded to results. Separate
laboratory technicians at the Uganda National TB Reference Lab performed mycobacterial cul-
ture on Lowenstein-Jensen solid media on two sputum specimens for each patient, as previ-
ously described [21]. Finally, consenting HIV-infected smear- and Xpert-negative individuals
without medical contraindication underwent diagnostic bronchoscopy with bronchoalveolar
lavage, with fluid sent for concentrated AFB-smear microscopy and culture and other microbi-
ologic assays, as previously described [25].
Statistical analysis
We performed univariate analyses of participant characteristics, and bivariate analyses strati-
fied by sputum quality type. We compared dichotomous variables using chi-squared tests, and
continuous variables using the Wilcoxon rank-sum test. We calculated simple diagnostic yield
as the proportion of each specimen type that were Xpert-positive. We also calculated sensitivi-
ties, specificities, positive and negative predictive values, and positive and negative likelihood
ratios for Xpert for each stratum of sputum quality in reference to a gold standard of mycobac-
terial culture on two sputum samples and, if available, on bronchoalveolar lavage. We com-
pared diagnostic yield by specimen type for our primary analysis. As a secondary analysis, we
also compared the sensitivities and specificities of samples of different sputum quality types to
confirm that differences in yield reflected differences in true-positive results. We selected the
comparisons of diagnostic yield for the primary analysis because this metric reflects how treat-
ment decisions are guided in routine practice. Another reason for this choice was that diagnos-
tic sensitivity, the usual standard metric for comparisons of performance, may have limitations
for the current analysis because sputum characteristics may reduce the yield of both the index
test and the reference test, sputum culture, leading to uncertain effects on diagnostic accuracy.
Finally, we conducted a multivariate analysis adjusting for age, gender, HIV status, CD4 count,
cigarette smoking, and alcohol use, in order to assess the extent to which differences in perfor-
mance reflect differences in patient characteristics versus differences in sputum characteristics.
Although sample size was based on convenience, we calculated 95% confidence intervals for all
study measures. We performed all analyses using STATA version 14.1 (Stata Corporation, Col-
lege Station, Texas).
Human subjects
The Makerere School of Medicine Research Ethics Committee, the Uganda National Council
for Science and Technology, the Mulago Hospital Institutional Review Board, the University
Effect of sputum quality on Xpert performance
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of California San Francisco Committee on Human Research, and the Yale Human Research
Protection approved the study.
Results
Study population
Of 3572 patients enrolled in the parent study from September 2008 through January 2016,
1782 (50%) were eligible for this analysis (Fig 1). Of those ineligible, 983 were smear positive
(28%), 346 were missing AFB-smear results (10%), 20 had sputum collected via induction
(0.6%), 408 had missing Xpert results (11%), and 33 had missing culture results (1%). There
were six time-periods when Xpert was not performed due to technical problems, accounting
for most (92%) of the missing Xpert data. Eighty-nine (4%) of 2223 smear-negative patients
had one indeterminate Xpert result and 14 (0.7%) remained indeterminate upon repeat. An
additional four (0.2%) failed to have a second Xpert test performed after the indeterminate
result, resulting in 18 (1%) with unobtainable Xpert test results.
Patients were generally young, with median age 34 years (inter-quartile range 28–44;
Table 1). Most participants were men (51%). A majority were HIV-infected (66%). Of those
Fig 1. Study population. Abbreviations: AFB, acid-fast bacilli; MTB, Mycobacterium tuberculosis; Xpert, Xpert MTB/RIF assay.
https://doi.org/10.1371/journal.pone.0180572.g001
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with HIV, a majority (68%) had CD4 counts200 cells/μL. Only 212 participants (12%) had a
previous history of TB. While only 26% of participants had smoked more than 99 cigarettes in
their lifetimes, a much higher proportion had ever drunk alcohol (65%).
Sputum quality
A majority of samples provided were mucoid (1296, 73%), with salivary being the next most
common sample type (286, 16%). Blood-stained (119, 7%) and purulent (81, 4%) samples were
less common. When comparing patients producing salivary sputum with those producing
other sputum types, there were few statistically significant differences. Women, however, were
significantly more likely to produce salivary sputum than men (19% vs. 13%, Risk Ratio (RR)
1.44 95% Confidence Interval (CI) 1.16–1.78, p = 0.001). While there was no significant associ-
ation between sputum type and HIV status, HIV-infected patients with CD4 counts >200
cells/μL were significantly less likely to produce salivary sputum than those with CD4 counts
200 cells/μL (11% vs. 18%, RR 0.63 95% CI 0.45–0.88, p = 0.005).
Diagnostic performance
Of 1782 smear-negative patients, 390 (22%) had positive Mycobacterium tuberculosis (MTB)
culture results, while 1392 (78%) had negative MTB cultures (Fig 1). Among MTB culture-pos-
itive patients, 207 had true-positive and 183 false-negative Xpert results. Among MTB culture-
negative patients, 1324 had true-negative and 68 false-positive Xpert results.
Patients with salivary sputum had a substantially higher proportion of samples that were
Xpert-positive (54/286, 19%, 95% Confidence Interval (CI) 15–24) compared with those with
all other sputum sample types (221/1496, 15%, 95% CI 13–17), yielding 4% (95% CI -0.8 to 9,
p = 0.08) more TB diagnoses. There were no significant differences between the proportions
positive for each sample type when compared to mucoid sputum (Fig 2). We saw a similar pro-
portion of MTB culture-positive results among those with salivary sputum (70/286, 25%, 95%
CI 20–30) as among those with all other sample types (320/1496, 21%, 95% CI 19–24), arguing
Table 1. Clinical and demographic characteristics.
Characteristic All Patients Salivary Non-Salivary p-ValueA
Sputum Sample Sputum Sample
(n = 1782) (n = 286) (n = 1496)
Median age (IQR), years 34 (28–44) 34 (28–43) 34.5 (28–44) 0.78B
Women (%) 868 (49) 165 (58) 703 (47) 0.001
Previous TB history (%) 212 (12) 29 (10) 183 (12) 0.32
HIV seropositive (%) 1170 (66) 183 (64) 987 (66) 0.52
CD4 count 200 cells/μLC 796 (69) 140 (78) 656 (67) 0.005
Tobacco smokerD (%) 467 (26) 66 (23) 401 (27) 0.19
Previous alcohol consumption 1158 (65) 172 (60) 986 (66) 0.061
MTB culture positive 390 (22) 70 (25) 320 (21) 0.25
Abbreviations: IQR, Inter-quartile range; TB, tuberculosis; MTB, Mycobacterium tuberculosis
Legend:
A Pearson chi-squared p-value utilized unless noted
B Wilcoxon rank-sum test utilized for age p-value
C Only for those who are HIV-seropositive; 13 responses missing
D Defined as those who have smoked more than 99 cigarettes in their lifetime
https://doi.org/10.1371/journal.pone.0180572.t001
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against a significant effect of specimen type on the yield of culture. Furthermore, we found
that those with positive Xpert results had higher semi-quantitative results on solid culture
Fig 2. Xpert proportion positive differences and unadjusted differences in sputum Xpert sensitivity
and specificity, stratified by sputum quality*. Legend: * Mucoid sputum utilized as the reference group.
https://doi.org/10.1371/journal.pone.0180572.g002
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media than those with negative results; this association did not significantly differ in compar-
ing those with salivary specimens to those with non-salivary specimens.
The overall diagnostic sensitivity of Xpert was 53% (95% CI 48–58), and the overall, speci-
ficity was 95% (95% CI 94–96; Table 2). Specificity did not vary meaningfully among sample
types, with similar results for blood-stained (94%; 95% CI 87–98), mucoid (95%; 95% CI 93–
96), salivary (96%; 95% CI 93–98), and purulent samples (97%; 95% CI 89–100); none of the
differences in specificity by sputum type were clinically or statistically significant (Fig 2). We
also considered whether the effect of a prior diagnosis of TB on the frequency of false positive
Xpert results differed by specimen type. Among those with salivary sputum, none of the eight
(0%) patients with false positive results had a history of prior TB while among those with non-
salivary sputum, nine of 60 (15%) did (Difference 15%, 95% CI -6.0 - + 24, p = 0.24). Stratified
by sputum sample type, Xpert sensitivity varied in a manner that reproduced the differences in
positive yield reported above, with blood-stained sputum identifying the lowest proportion
(28%; 95% CI 12–49) and salivary sputum producing the highest proportion (66%; 95% CI 53–
77) of TB patients. Xpert sensitivity was similar among purulent and mucoid specimens, with
a difference of +1% (95% CI -23 to +25, p = 0.95; Fig 2). However, salivary sputum was 13%
(95% CI +1 to +26, p = 0.04) more sensitive than mucoid sputum, and blood-stained sputum
was 24% (95% CI -42 to -5, p = 0.02) less sensitive than mucoid sputum. Positive likelihood
ratios (LR+) varied by sputum type, with blood-stained sputum providing the weakest LR+
(4.4; 95% CI 1.6–12) and salivary the strongest LR+ (17.7; 95% CI 8.8–36). Negative likelihood
ratios were similar for salivary (0.36; 95% CI 0.26–0.49), mucoid (0.50; 95% CI 0.45–0.57), and
purulent (0.49; 95% CI 0.29–0.81) sputum types, while blood-stained sputum had the weakest
negative likelihood ratio (0.77; 95% CI 0.60–0.99).
After adjusting for age, HIV status, CD4 count, gender, smoking, and alcohol use, the over-
all effect of sputum quality on Xpert sensitivity remained significant (p = 0.006), without
Table 2. Diagnostic performance of GeneXpert among 1782 study participants, stratified by sputum quality characteristics.
All Blood-stained Mucoid Purulent Salivary
Samples Sputum Sputum Sputum Sputum
n = 1782 n = 119 n = 1296 n = 81 n = 286
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Sensitivity, % 53 (48–58) 28 (12–49) 52 (46–58) 53 (28–77) 66 (53–77)
Specificity, % 95 (94–96) 94 (87–98) 95 (93–96) 97 (89–100) 96 (93–98)
PPV, % 75 (70–80) 54 (25–81) 74 (67–80) 82 (48–98) 85 (73–93)
NPV, % 88 (86–90) 83 (75–90) 88 (86–90) 89 (79–95) 89 (85–93)
LR+ 10.9 (8.5–13.9) 4.4 (1.6–11.9) 10.2 (7.7–13.6) 16.9 (4.0–71.2) 17.7 (8.8–35.8)
LR- 0.49 (0.44–0.55) 0.77 (0.60–0.99) 0.50 (0.45–0.57) 0.49 (0.29–0.81) 0.36 (0.26–0.49)
Abbreviations: CI, Confidence Interval; PPV, Positive Predictive Value; NPV, Negative Predictive Value; LR+, Positive Likelihood Ratio; LR-, Negative
Likelihood Ratio.
Legend: Below are the counts in each diagnostic accuracy category, with a single sputum Xpert as the index test, and mycobacterial culture on at least two
sputum samples and bronchoalveolar lavage (if available) as the reference standard test
All samples: 207 true positives, 183 false negatives, 68 false positives, 1324 true negatives.
Blood-stained: 7 true positives, 18 false negatives, 6 false positives, 88 true negatives.
Mucoid: 145 true positives, 133 false negatives, 52 false positives, 966 true negatives.
Purulent: 9 true positives, 8 false negatives, 2 false positives, 62 true negatives.
Salivary: 46 true positives, 24 false negatives, 8 false positives, 208 true negatives.
https://doi.org/10.1371/journal.pone.0180572.t002
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meaningful changes in the above-reported sensitivity differences. Adjusted sensitivity of sali-
vary sputum remained significantly different from mucoid samples (p = 0.02), as did adjusted
sensitivity of blood-stained sputum (p = 0.01).
Discussion
Specimen quality has long been assumed to be as an important predictor of the performance
characteristics of microbiologic tests, particularly those used to diagnose lower respiratory-
tract infections. Unfortunately, the amount and quality of evidence about how sputum quality
affects the performance of TB diagnostic tests is limited. In this prospective cross-sectional
study, we found no significant difference in diagnostic yield of Xpert testing between salivary
and non-salivary specimens among adults with negative sputum AFB-smear examinations in a
low-income country with high burdens of TB and HIV. In fact, we identified a strong trend
towards a higher diagnostic yield in salivary than in non-salivary specimens. These differences
were confirmed by a secondary comparison of diagnostic accuracy in reference to mycobacte-
rial culture. This analysis showed significantly higher diagnostic sensitivity of Xpert on salivary
samples as compared with the referent category, mucoid sputum samples, while blood-stained
sputum was associated with significantly lower sensitivity.
Macroscopic quality has long been emphasized in guidelines on the use of smear micros-
copy in TB evaluation. Despite this emphasis, there is only one published study of sputum
quality and smear microscopy, which demonstrated substantially higher sensitivity with puru-
lent or bloody sputum as compared with mucoid or salivary sputum among 170 TB patients
[20]. However, 40% had culture-negative TB, and it is unclear if these associations apply
equally to patients with microbiologically confirmed TB, or be relevant to less pauci-bacillary
populations. While a recent systematic review found no studies on the influence of sputum
quality on the performance of Xpert [16], we identified two subsequently published studies
addressing this question. One compared diagnostic sensitivity and specificity by sputum type
among 136 culture-confirmed TB patients and 703 culture-negative non-TB patients in
Kenya, but there were only a few modest differences by sample type and none of these reached
statistical significance [19]. The second study enrolled over 21,000 household contacts in Viet-
nam but almost all samples collected were mucoid, which prevented meaningful comparisons
with other sample types [17].
Thus, our finding that salivary sputum does not have lower but perhaps higher diagnostic
yield when testing for TB with Xpert may have great clinical importance. Salivary sputum has
been considered unsuitable for examination by smear microscopy, and therefore laboratory
staff have historically been trained to discourage patients from producing and submitting sali-
vary sputum samples in preference for other sample types. Our results suggest that the conven-
tional assumptions that salivary sputum is of lower quality and bloody sputum of higher
quality for smear microscopy do not apply to samples tested with Xpert. Given the observa-
tional study design, we were not able to explore reasons why salivary sputum may provide
greater sensitivity than other samples. Potential reasons could include: a greater bacillary load
of MTB DNA in saliva than in other sample types; a greater recovery of MTB DNA from sali-
vary sputum than from more viscous sample types; or more efficient amplification of MTB
DNA from saliva than from samples such as sputum that have a more complicated specimen
matrix that could include inhibitors of amplification. The last explanation is unlikely because
the Xpert assay includes a positive control to detect inhibitors in all samples.
Our findings about the enhanced yield of salivary sputum may be of additional importance
in high HIV-burden areas because of the inverse association we identified between CD4 count
and the likelihood of producing salivary sputum. Because those with lower CD4 counts are
Effect of sputum quality on Xpert performance
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also more likely to develop TB and to be smear-negative, it is crucial that they be tested with a
diagnostic tool that has high sensitivity and high likelihood of obtaining a true positive result
[15, 26]. Since salivary sputum had the highest diagnostic sensitivity of any specimen type
tested, salivary samples should not be rejected for Xpert testing. Additional studies might
explore whether saliva, particularly when obtained after coughing and prior to eating or oral
care, can provide comparable diagnostic sensitivity to that of other sputum types [27].
In contrast, blood-stained sputum appears less desirable for Xpert testing in smear-negative
populations. Xpert testing of blood-stained sputum missed twice as many TB cases as it diag-
nosed. A potential explanation for lower sensitivity could be that blood is a known inhibitor of
DNA amplification, although this is less likely because by design Xpert inhibition should be
detected by failed amplification of the internal positive control and reported as “Invalid”[28].
Nevertheless, our results do raise concern about the suitability of bloody sputum for molecular
testing, and merit further investigation to identify the mechanisms underlying the low sensitiv-
ity. Until then, practitioners may consider attempting to obtain a non-bloody sample if a
bloody specimen tests Xpert-negative.
Our study had some limitations. First, a majority of samples were mucoid (73%), resulting
in small sample sizes for other sputum types and relatively large confidence intervals for all
study measures. In particular, our primary analysis comparing diagnostic yield by specimen
type is underpowered, because the 95% confidence intervals for yield differences include clini-
cally important effects. Nevertheless, our sub-analyses were sufficiently powered to detect
meaningful differences in sensitivity among three of four sputum types. Second, our sub-analy-
ses could have been biased if the yield of sputum culture is also influenced by specimen quality.
However, direct comparisons showed no difference in culture yield, and even if underpowered,
the similarities in effect size and direction of our yield and accuracy analyses make this unlikely.
Furthermore, we may have misclassified some culture-negative TB patients as not having TB,
since we utilized solid rather than liquid culture media [29]. However, since our gold standard
was rigorously determined utilizing multiple mycobacterial culture samples, we believe that this
misclassification is minor and would not substantially bias our estimates. We may also have
occasionally misclassified sputum quality. However, we utilized well-trained laboratory technol-
ogists to assess macroscopic sputum quality and provided them with visual aids to promote
accurate readings. Therefore, any misclassification would likely be non-differential and unlikely
to impact our results. Finally, our study focused on sputum smear-negative patients, but Xpert
is now recommended as the first-line test for TB regardless of smear-status [15]. However, in
many settings, Xpert testing continues to be limited to smear-negative patients due to resource
constraints.
Our study also had many strengths. First, we carried out our study in a relevant population,
possible TB patients in a low-income country with a high TB burden. This helps make our
results generalizable to many other populations being tested with Xpert in high-burden,
resource-limited settings. Second, our study is the first of sufficient size and power to provide
meaningful comparisons of the effects of sputum quality on both Xpert diagnostic accuracy
and Xpert diagnostic yield. We therefore believe our study fills a crucial gap in understanding
Xpert testing.
In conclusion, for patients who are smear-negative, utilizing Xpert may provide a rapid
diagnosis that might have otherwise been missed. As it replaces smear microscopy in an
increasing number of high-burden countries, it has the potential to reduce the time and num-
ber of visits needed to obtain a diagnosis. Our findings, however, demonstrate the need to
exercise caution in collecting sputum for Xpert and in interpreting results because sputum
quality may impact test yield and sensitivity differently from what has been traditionally taught
for smear microscopy. In particular, it may be wise to pursue additional testing should a
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blood-stained sputum test negative, especially in high TB-burden communities. In addition,
laboratory staff should not reject salivary sputum for Xpert testing but accept it readily given
its higher sensitivity and potentially higher yield than other sample types. Future studies
attempting to replicate these findings and examining additional factors that may impact Xpert
diagnostic performance are warranted to help enhance the yield and sensitivity of Xpert
testing.
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